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Introduction: In selected patients with atrial fibrillation (AF) left atrial appendage (LAA) occlusion is an alternative to oral 
anticoagulation since the LAA is the source of thrombi in more than 90%. Combining transseptal radiofrequency AF 
ablation and LAA occlusion in symptomatic patients with AF and at high thromboembolic risk might be elegant and 
convenient. However, outcome data of concomitant AF ablation and LAA occlusion are scarce. We report our experience 
with combined procedures using a simplified approach. 
Method: We assessed all consecutive patients who underwent concomitant transseptal AF ablation and LAA occlusion 
using Amplatzer devices (St. Jude Medical, Plymouth, MN, USA) between 2002 and 2013. All patients had LAA occlusion 
performed under local anesthesia (one exception) at the end of the AF ablation procedure. LAA occlusion was guided by 
fluoroscopy only and without intraprocedural transesophageal echocardiography. 
Results: The concomitant procedure was performed in 20 patients (14 males), aged 66±9 years, CHA2DS2-VASc-score 
2.4±1.5 with an acute success rate of 100%. However, there were one bleeding from the femoral access site and one 
aneurysm formation both requiring surgical intervention as well as one subacute device embolization. The embolized 
device was retrieved using a vascular snare and the LAA was occluded with another device in the same session. After a 
mean follow-up of 30 months (4 to 119 months) there was no device embolization or cerebrovascular event. One patient 
died from congestive heart failure 10 years after the procedure. AF recurred in 9 patients (50%) compared to an overall 
success rate after the last procedure of 68% in patients with AF ablation alone in our center within the same time period 
(n=676; p=0.1).  
Conclusion: Concomitant LAA occlusion and transseptal AF ablation is feasible without intraprocedural 
echocardiographic guidance or general anesthesia. However, the acute complication rate for the combined approach is 
higher than expected for an AF ablation alone. The long-term safety is good. Compared to overall success rates of AF 
ablation alone AF recurrences may be more frequent. 
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Improved outcome following cardiac resynchronization therapy is related to higher doses of 
ACE inhibitors, angiotensin receptor antagonists and beta blockers and lower doses of 
diuretics 
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Introduction: Cardiac resynchronization therapy (CRT) is an established treatment option for patients with chronic heart 
failure (CHF), who are on optimal medical therapy. The impact of CHF medication optimization following CRT, however, 
has never been comprehensively examined. In the present study, we therefore examined the effect of CHF medication 
dosage on clinical outcome in CHF patients after CRT implantation. 
Method: A total of 185 patients were retrospectively followed up after CRT implantation. CHF medication of patients with 
a complete 24-month follow-up (or who reached a mortality endpoint prior to this time point) was continuously assessed. 
Patients with an improvement of the end-systolic volume index (ESVI) of ≥ 40 % were considered super-responder. The 
primary endpoint (death, heart transplantation, assist device implantation, or hospitalization for CHF) occurred in 83 
patients over a mean follow-up of 44.6 months. 
  
